文献速递前列腺癌

强效雄激素受体抑制后转移性去势抵抗性前列腺癌的管理:新型研究性治疗综述

Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-11-09

本综述总结了当前mCRPC的治疗选择,并重点介绍了新型研究性疗法的近期试验结果。雄激素靶向治疗和化疗仍是基础,但经重度治疗产生耐药的患者可能从PARPi、AR降解剂、Lu-PSMA放射配体治疗、免疫导向治疗及靶向耐药机制的药物中获益。随机试验的额外数据对于理解这些策略的疗效和耐受性仍是必要的。

要点

  • PARPi已获FDA批准用于HRR基因突变的mCRPC患者。
  • AR降解剂和Lu-PSMA放射配体治疗正在研究中。
  • 免疫导向治疗(PD-1抑制、BiTE、CAR-T)在早期试验中显示前景。

核心结论

  • PARPi、AR降解剂、PSMA靶向治疗、免疫导向治疗及靶向耐药机制的药物单用或联用可能改善mCRPC患者结局。
  • 需要随机试验的额外数据来理解这些治疗策略的疗效和耐受性。

研究设计与样本

  • 综述:检索Medline、PubMed及国际会议摘要,汇总mCRPC研究性治疗文献。

主要发现

  • 雄激素靶向治疗和化疗仍将是mCRPC治疗的基础。
  • 经重度治疗产生耐药的患者可能从新型治疗策略中获益。
  • PARPi已获FDA批准用于HRR基因突变的患者。
  • AR降解剂和Lu-PSMA放射配体治疗正在研究中。
  • 免疫导向治疗(PD-1抑制、BiTE技术、CAR-T细胞疗法)在早期试验中显示前景。

临床怎么用

  • 对于经强效雄激素受体抑制和化疗后进展的mCRPC患者,可考虑PARPi(若存在HRR基因突变)或临床试验中的新型疗法。

局限性

  • 需要随机试验数据进一步明确新型治疗策略的疗效和耐受性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Androgen-targeted therapy and chemotherapy are currently the mainstay of treatment in metastatic castration resistant prostate cancer (mCRPC). When progression occurs despite these therapeutic strategies, additional FDA-approved treatment options are lacking. However, there is a vast amount of emerging data surrounding novel investigational therapies in this space. METHODS: We reviewed and summarized the body of literature surrounding the current treatment options for mCRPC. Medline and Pubmed as well as abstracts from international congresses were utilized to gather relevant literature surrounding investigational treatment of mCRPC. We highlight the results of recent trials investigating the use of novel strategies to treat mCRPC. RESULTS: Androgen-targeted therapy and chemotherapy will remain foundational in the treatment of mCRPC. However, heavily pretreated patients who have developed resistance may benefit from novel therapeutic strategies. The use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPi) has now gained FDA approval for patients with homologous recombination repair (HRR) gene mutations. Novel androgen receptor (AR) degraders and the use of radioligand therapy (RLT) with Lu-PSMA-617 (Lu-PSMA) are under investigation. Immune-directed therapies, including programmed death (PD-1) inhibition, bi-specific T-cell engager (BiTE) technology, and chimeric antigen receptor (CAR) T-cell therapy, have shown promise in early phase trials. Further understanding of resistance mechanisms has led to additional therapeutic targets, including targeting the PI3K-Akt-mTOR pathway and enhancer of zester homolog 2 (EZH2). CONCLUSIONS: Based on our review of the literature, exciting new therapeutic strategies exist for the treatment of mCRPC. In particular, PARPi, AR degraders, PSMA-targeted therapies, immune-directed therapies, and agents targeting resistance mechanisms as monotherapy or in combination could improve patient outcomes. Additional data from randomized trials are necessary to understand the efficacy and tolerability of these treatment strategies.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Labriola MK, Atiq S, Hirshman N, et al. Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies. Prostate Cancer Prostatic Dis. 2020. PMID: 33168966. doi:10.1038/s41391-020-00299-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。